News

BioMarin Pharmaceutical has initiated a Phase I/II clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase, intended for the treatment of the lysosomal storage disorder mucopolysaccharidosis type IVA, or Morquio

“Our first-quarter sales growth is in line with our objectives,” commented Stéphane Bancel, bioMérieux’s chief executive officer. “In today’s difficult financial and economic climate, our product diversification, our

Novagali Pharma, a France-based ophthalmic pharmaceutical company, has successfully completed a new Phase II clinical study with Cyclokat, its formulation of cyclosporine. The results demonstrate statistically significant improvement

Medicure, a biopharmaceutical company engaged in the research, development and commercialization of novel small molecules to treat cardiovascular and neurological disorders, has reported a net loss of C$3.64m,

Dendreon has enrolled the first patient in a Phase I clinical trial of D3263 in patients with advanced cancer. D3263 is the company’s lead small molecule drug candidate

Before joining Sloning, Mr Merry has held several executive positions in the field of sales and marketing with companies such as Applied Biosystems, Millipore, or Qiagen, where he

Circassia has initiated a Phase II clinical study of its ToleroMune technology in allergy patients with asthma. The trial builds on positive Phase II results that demonstrated the

Under the terms of the agreement, DTL will market the Sonablate 500 high intensity focused ultrasound (HIFU) system as a mobile, ‘fee for use’ service to hospitals in

The agreement was entered into to advance the development of NovaBay’s Aganocide compounds by integrating extensive and ongoing clinical work at the university with NovaBay’s development program. Under